BriefHealth
The healthcare startup founded in 2022 is expanding to 3,920 square feet at 120 Ionia Ave. SW.
M
Read full storyMlive
Original source
Trending
OpenAI has solved the Navier-Stokes Millennium problem using $15m of AI effortExclusive – Secretary Scott Bessent: If China ‘Were to Pull Ahead of Us on AI, Nothing Else Matters’More than 600 flights in and out of U.K. cancelled due to air traffic control issueVocational education teachers threaten poll boycott over yearNo contradiction between respect to Ma Durga and our creative freedom: Theme artistsPunjab enforces ‘no work, no pay’ rule as employees extend strike till Sept 11Jaipur heritage, two roadmaps: BJP’s broad promise vs Cong’s 50Bybit Adds 24/7 FX Majors to Its Crypto Derivatives AccountOpenAI has solved the Navier-Stokes Millennium problem using $15m of AI effortExclusive – Secretary Scott Bessent: If China ‘Were to Pull Ahead of Us on AI, Nothing Else Matters’More than 600 flights in and out of U.K. cancelled due to air traffic control issueVocational education teachers threaten poll boycott over yearNo contradiction between respect to Ma Durga and our creative freedom: Theme artistsPunjab enforces ‘no work, no pay’ rule as employees extend strike till Sept 11Jaipur heritage, two roadmaps: BJP’s broad promise vs Cong’s 50Bybit Adds 24/7 FX Majors to Its Crypto Derivatives Account
Related Stories
Health1h ago
Pamela Anderson reveals the diagnosis that once cost her everything she had
Pamela Anderson opens up about her hepatitis C diagnosis, the fear it brought, and how treatment drained her savings before she finally found her cure.
HHola!
Health7h ago
AirNexis Therapeutics Announces that AN01, a Dual PDE3/4 Inhibitor Dry Powder Inhaler (DPI) Met its Primary Endpoint in a Phase 2b COPD Study (HSK39004-T1-202) Conducted in China by AirNexis' partner Haisco Pharmaceutical Group
REDWOOD CITY, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- AirNexis Therapeutics, Inc. ("AirNexis"), a clinical-stage biotech company developing therapeutics for pulmonary diseases, today announced results from a Phase 2b study of AN01, a dual PDE3/4 inhibitor DPI. The study, HSK39004-T1-202, was conducted in China by AirNexis' partner Haisco Pharmaceutical Group ("Haisco"). The Phase 2b study enrolled patients with chronic obstructive pulmonary disease (COPD) receiving background therapy of single or dual bronchodilator maintenance therapy who remained symptomatic despite such treatment. Data were presented earlier today at the 2026 European Respiratory Society (ERS) Congress in Barcelona, Spain. The ePoster will be available on the conference's website. AirNexis licensed AN01 (HSK39004 in China) from Haisco, which is developing the asset for the Greater China market; AirNexis holds development rights outside China.
GGlobe Newswire
Health1h ago
Postmemory: delineating the impact of trauma on the generation
Coined by American philosopher Marianne Hirsch, postmemory describes the relationship of the subsequent generation to the traumatic experiences of the previous generation, which they did not directly experience but ‘remember’ through stories and experiences transmitted to them
TThe Hindu
Health7h ago
Australian pollen season may be arriving early in eastern states
Australian pollen season may be arriving early in eastern states Medical Xpress Has hay fever season started early? And what’s the most common culprit? The Conversation What you need to know about seasonal illnesses this spring SBS Expat reveals health condition that's much worse in Australia: 'Every night at 4am' au.news.yahoo.com
GGoogle News